Engy Abdelmaguid
A bit about me I thrive on translating complex clinical evidence into actionable strategies that ensure innovative therapies reach the […]
JCA Meets AMNOG: German Benefit Assessments for Tarlatamab and Lurbinectedin Published
The German Federal Joint Committee (G-BA) has recently published its benefit assessments for tarlatamab and lurbinectedin, the second and third
Laurence Lapauw
I am motivated to contribute to translation of scientific evidence into clear key messages, which may be implemented to improve
Maj-Britt Paulsohn
I am passionate about translating complex scientific evidence into meaningful insights that support healthcare decision-making and improve patient access to
When Better Models Meet Missing Overlap
What the Itvisma JCA says about designing evidence for questions someone else will define. The new Joint Clinical Assessment
John Petty
A bit about me I am motivated by translating the evidence and data behind new and innovative treatments into clear
AMNOG 2.0: A Second Assessment Does Not Yet Make a Learning System
Germany may be about to make AMNOG more adaptive. But the important question is not whether there will be a
NICE Updates its Approach with a New Relevant EQ-5D-5L Dataset: What Does the Change Mean for Patient Access and how Should Companies Prepare?
On 27 August 2026, the National Institute for Health and Care Excellence (NICE) confirmed the adoption of the EuroQoL 5-Dimension 5-Level
Isabeau Vermeulen
A bit about me Isabeau enjoys working at the intersection of science and patient impact, with a focus on translating
Rory McAtamney
A bit about me I am motivated by improving patient access to effective medicines by generating robust, decision‑focused health economic
